Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686081 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Not yet
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07686081 is a Phase 3 study that has not yet begun recruiting, run by Vanda Pharmaceuticals. The registered enrollment target is 150 participants.
The verdict
NCT07686081, a Phase 3 study, has not yet begun recruiting, sponsored by Vanda Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
Interventions
- DRUG Placebo
- DRUG Ponesimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-09 |
| Est. Completion | 2029-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07686081
The ClinicalTrials.gov registry entry for NCT07686081 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07686081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07686081 about?
NCT07686081 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis". A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
What is the current status of trial NCT07686081?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-09. Estimated completion is 2029-08.
What interventions are being tested in trial NCT07686081?
The interventions under investigation include: Placebo (DRUG), Ponesimod (DRUG).
Who is sponsoring clinical trial NCT07686081?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.